Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RO7443904 |
| Synonyms | |
| Therapy Description |
RO7443904 is a bispecific antibody that targets both CD19 and CD28, resulting in cross-linking of CD28-positive T-cells to CD19-expressing tumor cells, potentially leading to enhanced cytotoxic response against CD19-positive tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RO7443904 | RO-7443904|RO 7443904|RG6333|RG-6333|RG 6333 | CD19 Antibody 21 CD28 Antibody 12 | RO7443904 is a bispecific antibody that targets both CD19 and CD28, resulting in cross-linking of CD28-positive T-cells to CD19-expressing tumor cells, potentially leading to enhanced cytotoxic response against CD19-positive tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|